



Melatonin and oral health

Shaik Ali Hassan¹, Sumit Bhateja²

¹ Dental Surgeon, Private Clinic Dr. Francis Maxillofacial Dental Clinic, Telangana, India

² HOD OMDR, Oral Medicine and Radiology, Manav Rachna Dental College, Haryana, India

Abstract

Melatonin has immunomodulatory and cancer prevention agent exercises, invigorates the expansion of collagen and bony tissue, and goes about as a defender against cell degeneration related with maturing and poison introduction. Emerging out of its cancer prevention agent activities, melatonin ensures against incendiary procedures and cell harm brought about by the poisonous derivatives of oxygen. In this review we will show how melatonin is helpful in oral health.

Keywords: melatonin, periodontal disease, saliva, dental caries, lymphocytes

Introduction

Melatonin is a substance discharged by different organs including the pineal organ, retina, bone marrow, the gastrointestinal tract, and the safe framework. Its principle work is the guideline of the circadian mood (day-night cycles) [1]. It plays a calming, antioncotic, and immunomodulatory job by rummaging free-radicals and using communications with cell film and intracellular proteins [2]. Melatonin is equipped for entering the oral cavity by diffusing into the saliva from the blood. As most of the melatonin stays bound to serum egg whites, the measure of melatonin in the saliva is around 33% of that present in the blood [3]. Melatonin predominantly applies cancer prevention agent impacts by interfacing with melatonin receptor 1 and melatonin receptor 2 receptors on cells [4, 5]. Maybe, an intense mitigating property of melatonin is connected to its capacity to go about as a scrounger of exogenous and endogenous responsive oxygen species and receptive nitrogen species [6].

Melatonin additionally assumes an immunomodulatory job [7], by controlling the emission of interleukin-2 and interferon-alpha and the ensuing actuation of CD4+ lymphocytes [8]. Also, melatonin purportedly invigorates the expansion and union of type I collagen and advances bone arrangement [9]. The extent of plasma melatonin entering the mouth through the salivary organs has all the earmarks of being moderately steady and ranges from 24% to 33%. It generally concurs that 70% of plasma melatonin is bound to egg whites.

Melatonin is nontoxic profoundly lipophilic indole, and this component encourages its entrance through cell films and its compartments. In any case, the most significant impact of melatonin appears to result from its strong cancer prevention agent, immunomodulatory, defensive, and anticancer properties [10, 11]. Along these lines, melatonin could be utilized remedially, for example, locally, in the oral cavity harm of mechanical, microbes, contagious, or viral birthplace, in postsurgical wounds brought about by tooth extractions and other oral medical

procedures, and in helping bone arrangement in different auto immunological issue, for example, Sjogren condition, in periodontal maladies, in poisonous impacts of dental materials, in dental inserts, and oral tumors [12, 13, 14].

Mechanism of Action

Even though the components by which melatonin regulates the pathways where it is included are at present not comprehended, it has been shown that it follows up on its objective cells/tissue through transmembrane G-protein-coupled receptors MT1, MT2, and MT3 or through vagrant atomic receptors of the retinoic corrosive receptor family [15]. However, in other specific organic settings, no particular receptors give off an impression of being required for melatonin's actions [16, 17] being a lipophilic particle, it can pass openly all through all cell and liquid compartments of the body having free access to all cells of the body and in this way offers an extra receptor-autonomous nonhormonal job of a free extreme forager in diminishing the oxidative pressure.

Melatonin on Oral Cavity

1. Dental caries

The nearness of melatonin in the oral pit in light of its discharge in saliva and given its valuable properties, it has been guessed that this hormone could have a cariostatic potential. For this reason, with the solid impact of diet on cariogenesis, Mechin and Tourny [17] proposed that melatonin, being inexhaustibly accessible in the groceries, may decrease the caries advancement with its cancer prevention agent movement. In their examination, Mechin and Tourny [17] tried the impacts of melatonin organization on caries advancement in rodents accepting a norm or an adjusted cariogenic diet 2000M, an enormous increment in the caries score was instigated by the cariogenic diet as thought about with the benchmark group. Besides, in bunches accepting melatonin, a

profoundly noteworthy abatement in the caries score was acquired.

2. Periodontal disease

Periodontal Disease is an oral provocative issue of the periodontium that influences the supporting tissues of the teeth (alveolar bone, gums, and periodontal tendon), prompting dynamic pulverization of connective tissue connection and alveolar bone. An outcome is a serious loss of supporting periodontal tissues and teeth, seen pervasively among grown-ups and more established individuals.

The etiology and pathogenesis of PD are not clear. Human gum disease and periodontitis are the consequences of unevenness in the bacterial species that colonize the oral depression and are described by complex associations between pathogenic microscopic organisms and the host's immune in flammatory responses [18, 19]. In the previous three decades, stamped propels have happened in our comprehension of the irresistible specialists of PD. There are more than 300 particular types of microscopic organisms present in the gingival region of the mouth, the greater part of which exists in a commensal relationship with the host. Be that as it May, three Gram-negative, anaerobic, or microaerophilic microorganisms species, known as periodontal pathogens (*Actinobacillus actinomycetemcomitans*, *Bacteroides forsythus*, and *Porphyromonas gingivalis*), have been recognized as being pervasive in periodontal plaque formations [20, 21, 22]. Moreover, inside the previous years, different herpes infections, for example, human cytomegalovirus and Epstein–Barr infection, have additionally risen as pathogens in the damaging periodontal disease [23]. Microbial parts, particularly lipopolysaccharide (LPS), can prompt an underlying penetrate of incendiary cells. Actuated macrophages blend and discharge an assortment of proinflammatory atoms, including a few interleukins (IL-1 α , IL- β , IL-6, and IL-8), tumor corruption factor α (TNF- α), prostaglandins (PGE2), and hydrolytic enzymes [24]. These cytokines enroll polymorphonuclear leukocytes (PMN) to the site of infection. PMN assumes a significant job in the etiology of PD, as they are the transcendent host safe reaction to oral bacterial contamination. Upon incitement by bacterial antigens, cytokines elevate the PMN to communicate grip particles, what's more, move out of the dissemination to the site of infection [25]. When PMN shows up here, they can prompt an autoamplification impact creating IL-8 to pull in more PMN into the disease site. This is exacerbated by the capacity of *P. gingivalis* to tweak the versatility and capacity of PMN inside the site of infection a decrease of IL-8 emission in epithelial cells, interceded by the bacterium, hinders the enlistment of PMN to the contaminated region. melatonin not exclusively would animate the resistant framework through the plasma division of the hormone would likewise manage the cost of nearby security however the salivary melatonin fraction [26] to all the more likely ensure the cell populaces influenced by the periodontal procedure from the ROS produced by the incendiary procedure. The salivation cell reinforcement limit was fundamentally lower in sick patients contrasted and controls. Furthermore, the proportion among salivation and serum cancer prevention agents was likewise fundamentally lower in ailing patients. It was recommended that the decrease in cancer prevention agent limit was either a direct causal factor in the PD patients or that the decrease was because

of a decrease in rummaging cell reinforcements interceded through an expansion in oxidative worry because of the pathogenesis of the illness.

Moreover, melatonin appears to have additionally an immediate impact over the cell populaces of the resistant framework. It is known, for example, that the metabolic results of periodontopathic microscopic organisms decline cytokine creation including IL-2 [27, 28]. IL-2 manages a progression of procedures in various cells of the resistant framework. A connection between IL-2 and melatonin was portrayed when it was discovered that melatonin invigorates the creation of IL-2 by T lymphocytes [29]. On the opposite end, IL-2 can regulate the union of melatonin at the degree of the pineal gland [30]. Without question, this proportional balance has significant outcomes at the hour of treatment of periodontal patients who have, somehow, a modified immunological framework. Accordingly, it was important to contemplate the changes in the connection between melatonin and IL-2 during periodontal pathologies. Also, prior studies [31, 32] demonstrated that an expansion in salivary and plasma melatonin brought about incitement of the CD4+ T cells, which have layer and atomic receptors for the hormone. This would invigorate the other invulnerable cell populaces through cytokine discharge (e.g., CD3+, CD19+, CD8+ cells), in this manner encouraging the host response to current oral contamination.

3. In the treatment of mucositis

The pathophysiology of mucositis isn't known in detail. An unpredictable speculation has been proposed to explain the instrument by which mucositis creates and settle. As per this, mucositis is a mind boggling process, isolated into four stages: an underlying provocative stage, an epithelial stage, a ulcerative/bacteriological stage, and a mending phase [32]. The theory guesses on the significance of the provocative reaction initiated in the included tissues by chemotherapy and ionizing radiation that happens through the enactment of intracellular and intercellular flagging pathways, controlling quality articulation of explicit proteins engaged with insusceptible and fiery procedures (e.g., cytokines, attachment molecules) [33, 34]. Of the numerous medications and strategies utilized to treat mucositis, none has been demonstrated to be consistently successful. Preliminaries exploring locally and foundationally applied medicines of mucositis incorporate immunomodulatory drugs, anticholinergic drugs, cytokines, antiviral medications, glutamine, and cell reinforcements. Among the cell reinforcements right now under scrutiny, the pineal hormone melatonin could be included, as it has been professed to have movement in the counteraction of mucositis [35, 36]. Locally and fundamentally applied melatonin has been appeared to forestall and treat mucositis in patients with cancer [37]. The pineal hormone melatonin restrains the creation of free radicals that intervene the poisonousness of chemotherapy.

Conclusion

Melatonin may have clinical applications in lessening oral illnesses, constraining tissue harm that is a consequence of free radicals, invigorating the insusceptible reaction, decreasing the dynamic loss of alveolar bone, advancing the relapse of indications of herpes viral contamination, blocking nearby fiery

sores, and conceivable treatment of xerostomia and oral malignant growth additionally with the biocompatibility of melatonin with the tissues of the oral hole and the need of resistance against cytotoxic and genotoxic activity of methacrylate-based dental materials.

References

1. Siu AW, Maldonado M, Sanchez-Hidalgo M, Tan DX, Reiter RJ. Protective effects of melatonin in experimental free radical-related ocular diseases. *J Pineal Res*. 2006; 40:101-109.
2. Cutando A, Aneiros-Fernandez J, Lopez-Valverde A, Arias-Santiago S, Aneiros-Cachaza J, Reiter RJ, *et al.* A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity. *Arch Oral Biol*. 2011; 56:944-950.
3. Cutando A, Galindo P, Gomez-Moreno G, Arana C, Bolanos J, Acuna-Castroviejo D, *et al.* Relationship between salivary melatonin and severity of periodontal disease. *J Periodontol*. 2006; 77:1533-1538.
4. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. *Mol Cell Endocrinol*. 2012; 351:152-166.
5. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, *et al.* Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. *J Immunol*. 1997; 159:574-581.
6. Manchester LC, Coto-Montes A, Boga JA, Andersen LPH, Zhou Z, Galano A, *et al.* Melatonin: an ancient molecule that makes oxygen metabolically tolerable. *J Pineal Res*. 2015; 59:403-419.
7. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. "A review of the multiple actions of melatonin on the immune system," *Endocrine*. 2005; 27(2):189-200.
8. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. "Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines," *Journal of Pineal Research*. 2000; 29(3):129-137.
9. Cutando A, Gómez-Moreno G, Arana C, *et al.*, "Melatonin stimulates osteointegration of dental implants," *Journal of Pineal Research*. 2008; 45(2):174-179.
10. Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. "Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin," *Journal of Pineal Research*. 2009; 46(2):128-139.
11. Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. "Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy," *Journal of Pineal Research*. 2006; 41(4):297-305.
12. Mechin JC, Toury C. "Action of cariogenic diet on fixation and retention of skeleton and teeth strontium in rats," *Revue Odonto Stomatologique*. 1973; 20(1):55-59.
13. Radio NM, Doctor JS, Witt-Enderby PA. "Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade," *Journal of Pineal Research*. 2006; 40(4):332-342.
14. Hallman M, Sennerby L, Lundgren S. "A clinical and histologic evaluation of implant integration in the posterior maxilla after sinus floor augmentation with autogenous bone, bovine hydroxyapatite, or a 20:80 mixture," *International Journal of Oral and Maxillofacial Implants*. 2002; 17(5):635-643.
15. Ekmekcioglu C. Melatonin receptors in humans: Biological role and clinical relevance. *Biomed. Pharmacother*. 2006; 60(3):97-108.
16. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R, *et al.* Melatonin: Nature's most versatile biological signal? *FEBS J*. 2006; 273(13):2813-38.
17. Mechin JA, Toury C. Action of melatonin on caries development in rats. *J Dent. Res*. 1976; 55(3):555.
18. Loe H. Principles of aetiology and pathogenesis governing the treatment of periodontal disease. *Int. Dent. J*. 1983; 33(2):119-26.
19. Olsen I. Update on bacteraemia related to dental procedures. *Transfus. Apher. Sci*. 2008; 39(2):173-8.
20. Chapple IL, Mason GI, Garner I, Matthews JB, Thorpe GH, Maxwell SR, *et al.* Enhanced chemiluminescent assay for measuring the total antioxidant capacity of serum, saliva and crevicular fluid. *Ann. Clin. Biochem*. 1997; 34(Pt 4):412-21.
21. Lamont RJ, Jenkinson HF. Life below the gum line: Pathogenic mechanisms of *Porphyromonas gingivalis*. *Microbiol. Mol. Biol. Rev*. 1998; 62(4):1244-63.
22. Page RC. Milestones in periodontal research and the remaining critical issues. *J Periodontal Res*. 1999; 34(7):331-9.
23. Jenkinson HF, Dymock D. The microbiology of periodontal disease. *Dent. Update*. 1999; 26(5):191-7.
24. Slots J, Kamma JJ, Sugar C. The herpesvirus–*Porphyromonas gingivalis*–periodontitis axis. *J Periodontal Res*. 2003; 38(3):318-23.
25. Kim J, Amar S. Periodontal disease and systemic conditions: A bidirectional relationship. *Odontology*. 2000; 94(1):10-21.
26. Gaiet J, Chollet-Martin S, Brion M, Hakim J, Gougerot-Pocidalo MA, Elbim C, *et al.* Interleukin-8 production by polymorphonuclear neutrophils in patients with rapidly progressive periodontitis: An amplifying loop of polymorphonuclear neutrophil activation. *Lab. Invest*. 1998; 78(6):755-62.
27. Asman B. Peripheral PMN cells in juvenile periodontitis. Increased release of elastase and of oxygen radicals after stimulation with opsonized bacteria. *J Clin. Periodontol*. 1988; 15(6):360-4.
28. Altman LC, Baker C, Fleckman P, Luchtel D, Oda D. Neutrophil-mediated damage to human gingival epithelial cells. *J Periodontal Res*. 1992; 27(1):70-9.
29. Cutando A, Gómez-Moreno G, Villalba J, Ferrera MJ, Escames G, Acuña-Castroviejo D, *et al.* Relationship between salivary melatonin levels and periodontal status in diabetic patients. *J Pineal Res*. 2003; 35(4):239-44.
30. Garcia-Mauriño S, Gonzalez-Haba MG, Calvo JR, Goberna

- R, Guerrero JM. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. *J Neuroimmunol.* 1998; 92(1-2):76-84.
31. Cutando A, Silvestre FJ. Melatonin: Implications at the oral level. *Bull. Group Int. Rech. Sci. Stomatol. Odontol.* 1995; 38(3-4):81-6.
 32. Sonis ST. Oral complications of cancer therapy. In: DeVita, V.T., Hellma, S., and Rosenberg, S.A. *Cancer: Principles and Practice of Oncology*, 5th ed. JB Lippincott, Philadelphia, 1993.
 33. Hallahan DE, Haimovitz-Friedman A, Kufe DW, Fuks Z, Weichselbaum RR. The role of cytokines in radiation oncology. *Important Adv. Oncol*, 1993, 71-80.
 34. Koj A. Initiation of acute phase response and synthesis of cytokines. *Biochim. Biophys. Acta.* 1996; 1317(2):84-94.
 35. Plevová P. Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: A review. *Oral Oncol.* 1999; 35(5):453-70.
 36. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. *Lancet Oncol.* 2005; 6(2):93-102.
 37. Herrstedt J. Prevention and management of mucositis in patients with cancer. *Int. J Antimicrob. Agents.* 2000; 16(2):161-3.